https://www.marketscreener.com/quote/stock/SPAGO-NANOMEDICAL-AB-120379773/news/First-patient-dosed-in-Spago-Nanomedical-s-clinical-phase-I-IIa-study-within-the-Tumorad-program-45532374/?utm_source=telegram&utm_medium=social&utm_campaign=share